Chief Scientific Officer · Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Rachael Brake

A named executive officer of Corbus Pharmaceuticals in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$839,867

Salary $453,980Stock awards $0Bonus $200,000

FY2022: $763,795

2nd of 3 named executive officers at Corbus Pharmaceuticals by FY2023 total.

3 named officers on file for Corbus Pharmaceuticals, FY2023

Rachael Brake’s pay file — $29

  • 2 fiscal years of pay, line by line
  • CRBP’s disclosed peer group of 1 company

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Corbus Pharmaceuticals’s whole pay program stands against its peers

  • Corbus Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CRBP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 2, 2024 (DEF 14A).

Free

Get Rachael Brake’s full pay file as a PDF — free

More than this page: up to 10 years of Rachael’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Rachael Brake compensation by year

Corbus Pharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as Corbus Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$427,779$453,980
Bonus$108,986$200,000
Stock awards$0$0
Option awards$211,573$161,735
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$15,457$24,152
Total$763,795$839,867

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Corbus Pharmaceuticals Holdings, Inc. DEF 14A filed April 2, 2024, accession 0000950170-24-040242, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Corbus Pharmaceuticals Holdings, Inc. filed document, accession 0000950170-24-040242. Every figure is read from that document and cited to the page and table it appears in. Filed April 2, 2024.

$764K
$840K
FY22
FY23
SalaryBonusOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option8,334—$22.50
Option10,307—$14.10
Option46,667—$4.26

Per the Outstanding Equity Awards at Fiscal Year-End table in Corbus Pharmaceuticals Holdings, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Corbus Pharmaceuticals’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Yuval CohenChief Executive Officer$1,137,622
Rachael Brake · this pageChief Scientific Officer$839,867
Sean MoranChief Financial Officer$717,256

The full Corbus Pharmaceuticals compensation record

free company brief

This page is one person within Corbus Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Corbus Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Corbus Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Rachael Brake's compensation dossier · One-time report. No refunds.